Lenvatinib Might Induce Activation of Host Immunity in Patients with Hepatocellular Carcinoma

INTRODUCTION: Atezolizumab, an immune checkpoint inhibitor, plus bevacizumab, a monoclonal antibody that binds to vascular endothelial growth factor (VEGF), is an approved first-line systemic treatment for unresectable hepatocellular carcinoma (HCC). Immune checkpoint inhibitors are more effective i...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagai, Hidenari, Mukozu, Takanori, Kobayashi, Kojiro, Nogami, Akira, Nagumo, Hideki, Mohri, Kunihide, Watanabe, Go, Amanuma, Makoto, Yoshimine, Naoyuki, Ogino, Yu, Matsui, Daigo, Daido, Yasuko, Matsukiyo, Yasushi, Matsui, Teppei, Wakui, Noritaka, Momiyama, Koichi, Higai, Koji, Matsuda, Takahisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872848/
https://www.ncbi.nlm.nih.gov/pubmed/36191570
http://dx.doi.org/10.1159/000527306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872848/
https://www.ncbi.nlm.nih.gov/pubmed/36191570
http://dx.doi.org/10.1159/000527306

Ejemplares similares